OBJECTIVES: The goal of this study was designed to assess prognostic values of simultaneous measurement of adipocytokines in systolic heart failure (HF) patients. METHODS: Patients with HF manifestations and left ventricular ejection fraction (LVEF) ≤ 50% were selected in this study. Gender, age, medications and serum biochemical data were recorded upon admissions. Adipocytokines including adiponectin, leptin, resistin, visfatin and retinol binding protein-4 were measured. RESULTS: A total of 108 (83 males and 25 females) patients were enroled. The age was 62±15 years and mean LVEF was 35%. Twenty patients died during 776±323 days follow-up. In univariate analysis, mortality was found to be associated with the log-transformed values of serum resistin (β=5·616, P=0·04), log-transformed values of serum adiponectin (β=4·377, P=0·038), age (β=1·071, P<0·001), NTHA functional status (β=3·752, P=0·001) and body mass index (β=0·858, P=0·012). Patients with higher level of serum resistin were associated with higher mortality (P=0·012). In multivariate analysis, mortality is associated with log-transformed values of serum resistin (β=3·666, P=0·045), age (β=1·044, P=0·017) and NTHA functional status (β=2·541, P=0·025). CONCLUSIONS: Serum resistin level was associated with higher mortality in systolic HF patients even after adjusting clinical parameters. Resistin may be an informative risk marker for systolic HF patients.
OBJECTIVES: The goal of this study was designed to assess prognostic values of simultaneous measurement of adipocytokines in systolic heart failure (HF) patients. METHODS:Patients with HF manifestations and left ventricular ejection fraction (LVEF) ≤ 50% were selected in this study. Gender, age, medications and serum biochemical data were recorded upon admissions. Adipocytokines including adiponectin, leptin, resistin, visfatin and retinol binding protein-4 were measured. RESULTS: A total of 108 (83 males and 25 females) patients were enroled. The age was 62±15 years and mean LVEF was 35%. Twenty patients died during 776±323 days follow-up. In univariate analysis, mortality was found to be associated with the log-transformed values of serum resistin (β=5·616, P=0·04), log-transformed values of serum adiponectin (β=4·377, P=0·038), age (β=1·071, P<0·001), NTHA functional status (β=3·752, P=0·001) and body mass index (β=0·858, P=0·012). Patients with higher level of serum resistin were associated with higher mortality (P=0·012). In multivariate analysis, mortality is associated with log-transformed values of serum resistin (β=3·666, P=0·045), age (β=1·044, P=0·017) and NTHA functional status (β=2·541, P=0·025). CONCLUSIONS: Serum resistin level was associated with higher mortality in systolic HFpatients even after adjusting clinical parameters. Resistin may be an informative risk marker for systolic HFpatients.
Authors: Daniel R Schwartz; Erika R Briggs; Mohammed Qatanani; Heloisa Sawaya; Igal A Sebag; Michael H Picard; Marielle Scherrer-Crosbie; Mitchell A Lazar Journal: Endocrinology Date: 2013-08-27 Impact factor: 4.736